Prevalence of AAS‐Positive Samples at Drug Abuse Laboratory Sweden Between 2014 and 2023 and Sub‐Study of Dual Use of AAS and Narcotics
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Kim Petterson Bohlin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. Hauptthemen laut MEDLINE: Substance Abuse Detection, Narcotics, Substance-Related Disorders, Anabolic Agents. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
It is of interest to investigate trends in AAS usage profile. Here we aimed to retrospectively study the prevalence of AAS‐positive samples based on 21,172 consecutive analyses from routine AAS testing 2014–2023. Moreover, 310 urine samples from 2022 to 2023 were reanalyzed for a broader AAS panel as well as for the presence of narcotics. Between 2014 and 2023, the frequency of reported AAS‐positive samples varied between 6% and 11%, with no trend discerned. The prevalence of samples containing several AAS also shows a similar distribution. The most common AAS detected were consistently testosterone, nandrolone, and drostanolone. Of the 310 urine samples reanalyzed, 80 male and 6 female samples were positive for AAS. Thirteen of the samples showed T/E 4–10, indicative of testosterone use, with no other AAS. Consequently, 4% of the samples might have been reported as false negatives. Of the AAS‐positive samples, amphetamine was found in 10% and 0% of the male and female samples, respectively. Cannabis was more often detected in AAS‐positive female samples (50%) than in male samples (25%), whereas cocaine was more commonly detected in male than in female samples (33 versus 17%). The prevalence of cannabis and amphetamine was like previous AAS studies conducted in Sweden, whereas the presence of cocaine in male samples was substantially higher. Co‐use of AAS and narcotics is a well‐known problem and highlights the importance of preventive actions and education/awareness of AAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
- Doping Control Laboratory, MU Clinical Pharmacology, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.
- Drugs of Abuse Laboratory, MU Clinical Pharmacology, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Lena Ekström
Zitieren
APA
Bohlin, K. P., Villén, T., Hopcraft, O., Pohanka, A., & Ekström, L. (2025). Prevalence of AAS‐Positive Samples at Drug Abuse Laboratory Sweden Between 2014 and 2023 and Sub‐Study of Dual Use of AAS and Narcotics. Drug Testing and Analysis. https://doi.org/10.1002/dta.3955
Vancouver
Bohlin KP, Villén T, Hopcraft O, Pohanka A, Ekström L. Prevalence of AAS‐Positive Samples at Drug Abuse Laboratory Sweden Between 2014 and 2023 and Sub‐Study of Dual Use of AAS and Narcotics. Drug Testing and Analysis. 2025. doi:10.1002/dta.3955
BibTeX
@article{Bohlin2025,
author = {Bohlin, Kim Petterson and Villén, Tomas and Hopcraft, Oscar and Pohanka, Anton and Ekström, Lena},
title = {Prevalence of AAS‐Positive Samples at Drug Abuse Laboratory Sweden Between 2014 and 2023 and Sub‐Study of Dual Use of AAS and Narcotics},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3955}
}
EUVIMED